Verdiva Bio valuation, funding and investors
Verdiva Bio works in cardiometabolic disorder therapeutics development, based in Guildford, United Kingdom. It has about 78 employees.
- Last round
- Growth · $457M · Sep 2025
- Valuation at last round
- $4.17B · implied
- Headcount
- 78 · growing
- Grade
- B
- Founded
- –
Verdiva Bio valuation today
VCMC values Verdiva Bio at $5.0B today, with a range of $3.1B to $7.0B and a grade of B. The valuation starts from its last funding round, a growth round in Sep 2025.
Valuation by date (24 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 10 Jan 2025 | $2.5B | $2.2B – $5.2B | $4.5B (+80%) | after a round | – | unknown | B | 0% |
| 1 Feb 2025 | $2.6B | $2.2B – $5.2B | $4.5B (+73%) | after a round | – | unknown | B | 0% |
| 1 Mar 2025 | $2.7B | $2.2B – $5.2B | $4.5B (+66%) | after a round | – | unknown | B | 0% |
| 1 Apr 2025 | $2.9B | $2.2B – $5.2B | $4.5B (+58%) | after a round | – | unknown | B | 0% |
| 1 May 2025 | $3.0B | $2.2B – $5.2B | $4.5B (+50%) | after a round | – | unknown | B | 0% |
| 1 Jun 2025 | $3.1B | $2.2B – $5.2B | $4.5B (+43%) | after a round | – | unknown | B | 0% |
| 1 Jul 2025 | $3.3B | $2.2B – $5.2B | $4.5B (+36%) | after a round | – | unknown | B | 0% |
| 1 Aug 2025 | $3.5B | $2.2B – $5.2B | $4.5B (+30%) | after a round | – | unknown | B | 0% |
| 1 Sep 2025 | $3.6B | $2.2B – $5.2B | $4.5B (+23%) | after a round | – | unknown | B | 0% |
| 20 Sep 2025 | $4.2B | $2.9B – $6.5B | $4.6B (+10%) | after a round | – | unknown | B | 0% |
| 1 Oct 2025 | $4.2B | $2.9B – $6.5B | $4.6B (+10%) | after a round | – | unknown | B | 0% |
| 1 Nov 2025 | $4.2B | $2.9B – $6.5B | $4.6B (+9%) | after a round | 55 | unknown | B | 0% |
| 1 Dec 2025 | $4.3B | $2.9B – $6.5B | $4.6B (+8%) | after a round | 55 | unknown | B | 0% |
| 1 Jan 2026 | $4.3B | $2.9B – $6.5B | $4.6B (+7%) | after a round | 55 | unknown | B | 0% |
| 1 Feb 2026 | $4.3B | $2.9B – $6.5B | $4.6B (+6%) | after a round | 55 | unknown | B | 0% |
| 1 Mar 2026 | $4.4B | $2.9B – $6.5B | $4.6B (+5%) | after a round | 55 | unknown | B | 0% |
| 1 Apr 2026 | $4.5B | $3.1B – $6.9B | $4.8B (+7%) | after a round | 70 | up | B | 0% |
| 1 May 2026 | $4.6B | $3.1B – $6.9B | $4.8B (+6%) | after a round | 70 | up | B | 0% |
| 1 Jun 2026 | $4.7B | $3.2B – $7.0B | $4.9B (+5%) | after a round | 76 | growing | B | 0% |
| 1 Jul 2026 | $4.8B | $3.2B – $7.0B | $4.9B (+4%) | after a round | 76 | growing | B | 0% |
| 1 Aug 2026 | $4.8B | $3.2B – $7.0B | $4.9B (+2%) | after a round | 76 | growing | B | 0% |
| 1 Sep 2026 | $4.9B | $3.2B – $7.0B | $4.9B (+1%) | after a round | 76 | growing | B | 0% |
| 1 Oct 2026 | $5.0B | $3.2B – $7.0B | $5.0B (0%) | after a round | 78 | growing | B | 0% |
| 24 Oct 2026 | $5.0B | $3.1B – $7.0B | $5.0B (0%) | after a round | 78 | growing | B | 0% |
Key facts about Verdiva Bio
- Founded
- Not on record
- Headquarters
- Guildford, United Kingdom
- Employees
- about 78 +42% in a year
- Total raised
- $868M
- Funding rounds
- 2
- Last round
- Growth Equity Sep 2025
Verdiva Bio was founded by Khurem Farooq.
Verdiva Bio funding history
Verdiva Bio has 2 funding rounds on record, from Jan 2025 to Sep 2025, $868M in total. The latest disclosed valuation is $2.50B post-money (Series A, Jan 2025).
Growth Equity 19 Sep 2025
Led by Forbion, General Atlantic; with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital.
Sources: insidermedia.com, bioindustry.org, fiercebiotech.com and 3 more
$457M
Series A 9 Jan 2025
Led by Forbion, General Atlantic; with RA Capital, OrbiMed, Logos Capital, Lilly Asia Ventures, LYFE Capital.
Sources: techfundingnews.com, bioindustry.org, techfundingnews.com
$411M
$2.50B post-money
Verdiva Bio investors
9 investors have backed Verdiva Bio; Forbion and General Atlantic led at least one round.
- General Atlantic lead, 2 rounds
- Lilly Asia Ventures 2 rounds
- Logos Capital
- LYFE Capital
What Verdiva Bio does
Verdiva Bio works in pharmaceutical products, with 11 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals.
Verdiva Bio Limited is a British biotechnology company engaged in the development of therapies for obesity, cardiometabolic disorders, and related complications. The company focuses on advancing treatments that address gut-brain biology and utilizes oral and subcutaneous amylin molecules, as well as other therapeutic programs, to develop novel approaches for weight management and metabolic health.
Description from Veridion's company data.
Products and services
- Cardiometabolic Disorder Therapeutics Development
- Obesity Treatment Therapeutics Development
- Gut-Brain Biology Therapeutics Research
- GLP-1 Receptor Agonist Development
- Amylin Analog Development
- Oral Drug Formulation Development
- Subcutaneous Drug Formulation Development
- Combination Therapy Development
- Preclinical Drug Candidate Development
- Clinical Drug Candidate Development
- Cardiometabolic Health Innovation Acceleration
Markets
- Healthcare
- Biotechnology
- Pharmaceuticals
Technology
- Oral GLP-1 Peptide Agonists
- Oral Amylin Analogues
- Subcutaneous Amylin Analogues
- Gut-Brain Biology Therapeutics
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 541714 Research and Development in Biotechnology (except Nanobiotechnology) 100% match
Questions about Verdiva Bio
What is Verdiva Bio worth?
Valuation $5.0B (range $3.1B to $7.0B), as of 24 Oct 2026. The last disclosed valuation was $2.50B (Series A, Jan 2025).
Has Verdiva Bio raised money?
Verdiva Bio has 2 funding rounds on record, from Jan 2025 to Sep 2025, $868M in total. The latest disclosed valuation is $2.50B post-money (Series A, Jan 2025).
Who has invested in Verdiva Bio?
Forbion, General Atlantic, Lilly Asia Ventures, OrbiMed, RA Capital and Logos Capital, and 3 more. Lead investors include Forbion and General Atlantic.
How many people work at Verdiva Bio?
About 78, up 42% over the last year. Headcount grew from 55 in Nov 2025 to 78 in Oct 2026.
What does Verdiva Bio do?
Verdiva Bio works in pharmaceutical products, with 11 recorded offerings and customers in healthcare, biotechnology and pharmaceuticals. Its main offerings are cardiometabolic disorder therapeutics development, obesity treatment therapeutics development and gut-brain biology therapeutics research.
Where is Verdiva Bio based?
Verdiva Bio is based in Guildford, United Kingdom; its founding year is not on record. It has about 78 employees, up 42% over the last year.